Distribution and Deposition of Magnetic Resonance Gadolinium Contrast Agents in Body: Current Status

LIU Zhe,CHENG Yan-nan,YANG Jian
DOI: https://doi.org/10.12015/issn.1674-8034.2017.09.014
2017-01-01
Abstract:Contrast-enhanced Magnetic resonance imaging (CE-MRI) is widely used in diagnosis and differential diagnosis diseases due to the high relaxation rate of gadolinium contrast agent. In the United States, more than 10 million patients accounting for 40%—50% of all MRI examinations undergoing CE-MRI which is considered as a safety method. But many literatures have reported that gadolinium contrast agent administration have been associated with nephrogenic systemic fibrosis (NSF) in whom with severely compromised renal function, some found that gadolinium could deposite in the skin, some organs and bone tissues. Recently, more studies have shown obviously evidence that gadolinium may deposit in some specific brain structures who with nomal renal function, such as globus pallidus and dentate nucleus. After repeated CE-MRI examinations we could find higher signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images. However, its mechanism and clinical significances remain to be unclear. Therefore, this paper will review the literatures on the application of magnetic resonance gadolinium contrast agent, summarizing the classifications and risk levels, biodistribution and deposition, possible mechanism and clinical significance, providing a powerful reference in selection of gadolinium contrast in clinic.
What problem does this paper attempt to address?